The novel anticoagulants: The surgeons' prospective

Fadi E. Shamoun, Elvis N. Martin, Samuel R. Money

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Anticoagulants can complicate the approach to the management of patients undergoing operative interventions. We review new anticoagulants that have been introduced recently to the market or that are undergoing investigations for treatment of nonvalvular atrial fibrillation and venous thromboembolism prophylaxis: Dabigatran, rivaroxaban, apixiban, and edoxaban.

Original languageEnglish (US)
Pages (from-to)303-307
Number of pages5
JournalSurgery (United States)
Volume153
Issue number3
DOIs
StatePublished - Mar 2013

Fingerprint

Anticoagulants
Venous Thromboembolism
Atrial Fibrillation
Surgeons
Therapeutics
Dabigatran
Rivaroxaban
edoxaban

ASJC Scopus subject areas

  • Surgery

Cite this

The novel anticoagulants : The surgeons' prospective. / Shamoun, Fadi E.; Martin, Elvis N.; Money, Samuel R.

In: Surgery (United States), Vol. 153, No. 3, 03.2013, p. 303-307.

Research output: Contribution to journalArticle

Shamoun, FE, Martin, EN & Money, SR 2013, 'The novel anticoagulants: The surgeons' prospective', Surgery (United States), vol. 153, no. 3, pp. 303-307. https://doi.org/10.1016/j.surg.2012.09.016
Shamoun, Fadi E. ; Martin, Elvis N. ; Money, Samuel R. / The novel anticoagulants : The surgeons' prospective. In: Surgery (United States). 2013 ; Vol. 153, No. 3. pp. 303-307.
@article{805bf360f2d14cb096267a4b182328be,
title = "The novel anticoagulants: The surgeons' prospective",
abstract = "Anticoagulants can complicate the approach to the management of patients undergoing operative interventions. We review new anticoagulants that have been introduced recently to the market or that are undergoing investigations for treatment of nonvalvular atrial fibrillation and venous thromboembolism prophylaxis: Dabigatran, rivaroxaban, apixiban, and edoxaban.",
author = "Shamoun, {Fadi E.} and Martin, {Elvis N.} and Money, {Samuel R.}",
year = "2013",
month = "3",
doi = "10.1016/j.surg.2012.09.016",
language = "English (US)",
volume = "153",
pages = "303--307",
journal = "Surgery (United States)",
issn = "0039-6060",
publisher = "Mosby Inc.",
number = "3",

}

TY - JOUR

T1 - The novel anticoagulants

T2 - The surgeons' prospective

AU - Shamoun, Fadi E.

AU - Martin, Elvis N.

AU - Money, Samuel R.

PY - 2013/3

Y1 - 2013/3

N2 - Anticoagulants can complicate the approach to the management of patients undergoing operative interventions. We review new anticoagulants that have been introduced recently to the market or that are undergoing investigations for treatment of nonvalvular atrial fibrillation and venous thromboembolism prophylaxis: Dabigatran, rivaroxaban, apixiban, and edoxaban.

AB - Anticoagulants can complicate the approach to the management of patients undergoing operative interventions. We review new anticoagulants that have been introduced recently to the market or that are undergoing investigations for treatment of nonvalvular atrial fibrillation and venous thromboembolism prophylaxis: Dabigatran, rivaroxaban, apixiban, and edoxaban.

UR - http://www.scopus.com/inward/record.url?scp=84873997956&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873997956&partnerID=8YFLogxK

U2 - 10.1016/j.surg.2012.09.016

DO - 10.1016/j.surg.2012.09.016

M3 - Article

C2 - 23218887

AN - SCOPUS:84873997956

VL - 153

SP - 303

EP - 307

JO - Surgery (United States)

JF - Surgery (United States)

SN - 0039-6060

IS - 3

ER -